Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: Frequency and prognosis in 467 patients without cranial irradiation for prophylaxis

Cancer

Volumn 106, Issue 12, 2006, Pages 2540-2546

  Sancho, Juan Manuel ^a,b   Ribera, Josep Maria ^a,b   Oriol, Albert ^a,b   Hernandez Rivas, Jesus Maria ^c   Rivas, Concepcion ^d   Bethencourt, Concepcion ^e   Parody, Ricardo ^f   Deben, Guillermo ^g   Bello, Jose Luis ^h   Feliu, Evarist ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g Hematology Department   (Spain)

^h Instituto de Salud Carlos III   (Spain)

Author keywords

Acute lymphoblastic leukemia; Central nervous system; Intrathecal; Prophylaxis; Recurrence

Indexed keywords

CYTARABINE; HYDROCORTISONE; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; FEMALE; FREQUENCY ANALYSIS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RADIATION DOSE; REVIEW; SKULL IRRADIATION; STEM CELL TRANSPLANTATION; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; CYTARABINE; FEMALE; HUMANS; HYDROCORTISONE; INCIDENCE; LACTATE DEHYDROGENASES; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 33745192655     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21948     Document Type: Review

References (32)

1. Gokbuget N, Hoelzer D. Meningeosis leukaemica in adult acute lymphoblastic leukaemia. J Neurooncol. 1998;38:167-180.
2. Pinkel D, Woo S. Prevention and treatment of meningeal leukemia in children. Blood. 1994;84:355-366.
3. Morris EC, Harrison G, Bailey CC, et al. Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia. Br J Haematol. 2003;120:787-789.
4. Winick NJ, Smith SD, Shuster J, et al. Treatment of CNS relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1993;11:271-278.
5. Hill FG, Richards S, Gibson B, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol. 2004;124:33-46.
6. Pui CH. Towards optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J Clin Oncol. 2003;21:179-181.
7. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. J Clin Oncol. 1993;11:520-526.
8. Pui CH, Mahmoud H, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
9. Ritchey AK, Pollock BH, Lauer SJ, Andejeski Y, Buchanan GR. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1999;17:3745-3752.
10. Sanders KE, Ha CS, Cortes-Franco JE, Koller CA, Kantarjian HM. The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia. Cancer. 2004;100:2176-2180.
11. Surapanemi UR, Cortes JE, Thomas D, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002;94:773-779.
12. Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult lymphoblastic leukemia. J Clin Oncol. 2002;20;2464-2471.
13. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788-2801.
14. Omura GA, Bass D. Prognostic factor analysis of central nervous system relapse in adult acute lymphoblastic leukemia. A Southeastern Cancer Study Group report. Am J Clin Oncol. 1994;17:93-96.
15. Cortes J. Central nervous system involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15:145-162.
16. Lazarus HM, Richards SM, Chopra R, et al. Adult patients with acute lymphoblastic leukemia (ALL) and central nervous system (CNS) leukemia at diagnosis may attain durable complete remissions (CR). Results from the international ALL trial (MRC UKALL-XII/ECOG E2993) [abstract]. Blood. 2004;104:204b.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of acute leukaemias. French-American-British (FAB) Co-operative Group. Br J Haematol. 1976;33:451-458.
18. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
19. Ribera JM, Ortega IJ, Oriol A, et al., and Members of PETHEMA Cooperative Group. Spanish Society of Haematology. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukaemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Haematologica. 1998;83:222-230.
20. Ribera JM, Oriol A, Bethencourt C, et al. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica. 2005;90:1346-1356.
21. Ribera JM, Oriol A, Sanz MA, et al. Results of PETHEMA ALL-96 protocol for standard risk adult ALL patients [abstract]. Hematology J. 2004;5(Suppl 2):S134.
22. Oriol A, Ribera JM, Esteve J, et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica. 2003;88:445-453.
23. Kaplan GL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. Peto R, Pike MC. Conservatism of the approximation (O-E)2/E in the log-rank test for survival data or tumour incidence data. Biometrics. 1973;29:579-584.
25. Vilmer E, Suciu S, Fester A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia. 2000;14:2257-2266.
26. Manera R, Ramirez I, Mullins J, et al. Pilot studies of species-specific chemotherapy of childhood acute lymphoblastic leukemia using genotype and immunophenotype. Leukemia. 2000;14:1354-1361.
27. Bassan R, Intermesoli T, Di Bona E, et al. Central nervous system involvement in adult acute lymphoblastic leukaemia: retrospective analysis from Northern Italy Leukaemia Group (NILG) on 687 total patients (1979-2004) [abstract]. Haematologica. 2005;90(s2):167.
28. Annino L, Vegna ML, Camera A, et al., for the GIMEMA Group. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863-871.
29. Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329:314-319.
30. Kantarjian HM, Walters RS, Smith TL, et al. Identification of risk groups for development of central nervous system leukaemia in adults with acute lymphocytic leukaemia. Blood. 1988;72:1784-1789.
31. Nagatoshi Y, Kawano Y, Nagayama J, Okamura J. Treatment of isolated central nervous system relapse in high-risk lymphoid malignancy with allogeneic bone marrow transplantation and extended intrathecal therapy. Br J Haematol. 2004;125:766-768.
32. Messina C, Valsecchi MG, Arico M, et al., on behalf of the AIEOP/FONOP-TMO Group. Autologous bone marrow transplantation for treatment of isolated central nervous system relapse of childhood acute lymphoblastic leukemia. Bone Marrow Transplant. 1998;21:9-14.